Does Mode of Surgical Intervention Based on Oncotype DX Score Influence Disease Recurrence in Early Breast Cancer?

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource
Language
Englisch

Bibliographic citation
Does Mode of Surgical Intervention Based on Oncotype DX Score Influence Disease Recurrence in Early Breast Cancer? ; volume:06 ; number:02 ; year:2020 ; pages:e135-e138
The surgery journal ; 06, Heft 02 (2020), e135-e138

Contributor
Aherne, T. M.
Boland, M. R.
Catargiu, D.
Bashar, K.
McVeigh, T. P.
Brodie, C.
Sweeney, K. J.

DOI
10.1055/s-0040-1712537
URN
urn:nbn:de:101:1-2020082009171529571052
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:49 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Aherne, T. M.
  • Boland, M. R.
  • Catargiu, D.
  • Bashar, K.
  • McVeigh, T. P.
  • Brodie, C.
  • Sweeney, K. J.

Other Objects (12)

Breast Cancer with Low Recurrence Score on Oncotype DX©: Interplay Between Early Recurrence, Lobular Histology and BRCA Mutation

Breast Cancer with Low Recurrence Score on Oncotype DX©: Interplay Between Early Recurrence, Lobular Histology and BRCA Mutation

Oncotype DX Breast Recurrence Score Test : klinische Erfahrungen mit dem genomischen Oncotype DX Breast Recurrence Score Test bei der Entscheidung für oder gegen eine Chemotherapie des frühen, hormonrezeptorpositiven, HER2-negativen Mammakarzinoms

Fallstudiensammlung

Oncotype DX Breast Recurrence Score Test : klinische Erfahrungen mit dem genomischen Oncotype DX Breast Recurrence Score Test bei der Entscheidung für oder gegen eine Chemotherapie des frühen, hormonrezeptorpositiven, HER2-negativen Mammakarzinoms

Vergleichende Untersuchung des Oncotype DX Recurrence-Score und Genexpressionstests MammaTyper beim invasiven Mammakarzinom

Hochschulschrift

Vergleichende Untersuchung des Oncotype DX Recurrence-Score und Genexpressionstests MammaTyper beim invasiven Mammakarzinom

Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer

Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer

Vergleich immunhistochemischer Markerprofile Her2/neu negativer, hormonrezeptorpositiver Mammakarzinome mit dem Recurrence-Score des OncotypeDX®.

Vergleich immunhistochemischer Markerprofile Her2/neu negativer, hormonrezeptorpositiver Mammakarzinome mit dem Recurrence-Score des OncotypeDX®.

BCL-2 expression aids in the immunohistochemical prediction of the Oncotype DX breast cancer recurrence score

BCL-2 expression aids in the immunohistochemical prediction of the Oncotype DX breast cancer recurrence score

Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data

Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data

Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results

Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results

DX.

Abschnitt

DX.

DX

Graffiti | Streetart

DX

Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer

Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer

MiRNA expression deregulation correlates with the Oncotype DX® DCIS score

MiRNA expression deregulation correlates with the Oncotype DX® DCIS score

Related objects